We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Study Reveals Basis for Development of a Universal Flu Vaccine

By LabMedica International staff writers
Posted on 26 Mar 2013
Researchers attempting to develop a "universal" flu vaccine have suggested that a multifocal approach based on primed immune cells and virus specific non-neutralizing antibodies may result in long-term protection from multiple strains of the influenza virus.

Investigators at the University of Pennsylvania (Philadelphia, USA) based their work on studies that showed that T lymphocytes were capable of mediating protection against multiple viral strains through recognition of internal, more conserved, influenza virus proteins. More...


They reported in the March 14, 2013, online edition of the journal PLOS Pathogens that influenza virus-specific CD8+ T-cells or virus-specific non-neutralizing antibodies were each relatively ineffective at conferring protective immunity alone. However, when administered together virus-specific CD8 T-cells and non-neutralizing antibodies cooperatively elicited robust protective immunity. This synergistic improvement in protective immunity was dependent, at least in part, on alveolar macrophages and/or other lung phagocytes.

“The two-pronged approach is synergistic, so by enlisting two suboptimal vaccine approaches, we achieved a better effect than each alone in an experimental model,” said senior author Dr. E. John Wherry, associate professor of microbiology at the University of Pennsylvania,. “Now, we are rethinking past approaches and looking for ways to combine T-cell vaccines and antibody vaccines to make a more effective combined vaccine. Overall, our studies suggest that an influenza vaccine capable of eliciting both CD8+ T-cells and antibodies specific for highly conserved influenza proteins may be able to provide protection in humans, and act as the basis for a potential "universal" vaccine.”

Related Links:
University of Pennsylvania



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.